BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
4.010
-0.060 (-1.47%)
Mar 5, 2026, 4:00 PM EST - Market closed
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,794,204
Market Cap
28.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% |
| Jul 31, 2021 | 6 | 0 | - |
| Aug 1, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| IGC Pharma | 70 |
| Werewolf Therapeutics | 39 |
| Lantern Pharma | 24 |
| AN2 Therapeutics | 22 |
| Tempest Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Rein Therapeutics | 11 |
BCTX News
- 15 hours ago - BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - GlobeNewsWire
- 15 days ago - BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement - GuruFocus
- 15 days ago - BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - GlobeNewsWire
- 16 days ago - BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - GlobeNewsWire
- 5 weeks ago - BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment - GuruFocus
- 5 weeks ago - BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation - GlobeNewsWire
- 5 weeks ago - BriaCell (BCTX) Reports Promising Phase 2 Survival Data - GuruFocus
- 5 weeks ago - BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients - GlobeNewsWire